A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522368-34-00

Acronym

MNA-001-01

Enrollment

112

Registered

2025-09-04

Start date

2025-09-05

Completion date

Unknown

Last updated

2025-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s Disease

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026